The past decade has seen tremendous developments in novel cancer therapies through the
targeting of tumor-cell-intrinsic pathways whose activity is linked to genetic alterations and …

TUMOR ANTIGENS RECOGNIZED BY T LYMPHOCYTES Page 1 Annu. Rev, Immunol, 1994.
12:337-65 Copyright © 1994 by Annual Reviews hTc. All rights reserved TUMOR ANTIGENS …

Cancer somatic mutations can generate neoantigens that distinguish malignant from normal
cells,,,,,,. However, the personalized identification and validation of neoantigens remains a …

Monoclonal antibodies represent an attractive therapeutic tool as they are highly specific for
their targets, convey effector functions and enjoy robust manufacturing procedures …

Most tumor-associated antigens represent self-proteins and as a result are poorly
immunogenic due to immune tolerance. Here we show that tolerance to carcinoembryonic …

VIRUSES that are non-or poorly cytopathic have developed various strategies to avoid
elimination by the immune system and to persist in the host1–3. Acute infection of adult mice …

Background Patients with follicular lymphoma may survive for periods of less than 1 year to
more than 20 years after diagnosis. We used gene-expression profiles of tumor-biopsy …

In this pilot study, we investigated the ability of autologous dendritic cells pulsed ex vivo with
tumor–specific idiotype protein to stimulate host antitumor immunity when infused as a …

IgG antibodies mediate a diversity of immune functions by coupling of antigen specificity
through the Fab domain to signal transduction via Fc-Fc receptor interactions. Indeed …

Purpose Combining tumor antigens with an immunostimulant can induce the immune
system to specifically eliminate cancer cells. Generally, this combination is accomplished in …